Remy Peptides · For in-vitro laboratory research only. Not for human or veterinary use.Research Use Only
Update History ▾
June 4, 2026: Initial publication, drawing on the Remy TB-500 thymosin beta-4 research profile, current product-catalog data, and peer-reviewed and official sources.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR - Research Vial Summary

TB-500 is a synthetic fragment of thymosin beta-4 (also written TB500), so the sourcing question comes down to confirming the vial is what the label says and reading its COA — not equating it with the full-length protein or its regulated trials. Remy Peptides currently lists TB-500 10mg Vial as In stock, with 10mg · Lyophilized research vial and AED 290-350 pricing shown in the product catalog. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.

Compliance note: this is a research-use-only product support article. It does not provide human-use dosing, treatment advice, veterinary guidance, disease-management claims, or administration instructions.

Verifying TB-500 before you order

TB-500 is written several ways — you will see it as TB500, as tb 500, and described as a thymosin beta-4 fragment — so anyone searching buy tb 500 or tb-500 dubai is really asking two questions at once: which vial to buy, and whether it is the synthetic fragment or the full native protein. The sections below cover that identity boundary, how to confirm HPLC purity and compound identity (the substance behind a tb 500 coa), what the published thymosin beta-4 research does and does not establish, and how researchers in Dubai and the UAE can verify a supplier before they buy a TB-500 vial.

For current product facts, start with TB-500 10mg Vial. This guide adds the surrounding evidence, supplier-verification, and compliance context around that listing.

Evidence Map and Translation Limits

Thymosin beta-4 is a 43-amino-acid actin-sequestering protein with a large repair-biology literature, while TB-500 in research catalogs is generally discussed as a synthetic Tβ4-derived fragment rather than the full native protein.[1] Clinical-trial searches around ophthalmic Tβ4 formulations help explain the evidence boundary but do not validate retail research-vial claims.[2]

Research layer What the literature supports What it means for sourcing
Identity boundary Full-length thymosin beta-4 and the market TB-500 fragment are not the same molecule and should not be treated as one. Confirm the listing names the fragment plainly and does not borrow full-protein claims.
Evidence tier The actin-binding literature is mechanistic and model-heavy; human clinical work is concentrated in specific regulated formulations. Treat the human data as early-stage and formulation-specific, not as a basis for any outcome claim.
Dubai product intent A local researcher needs vial size, price range, stock status, and a verifiable COA route. Confirm vial size, AED tier, stock, and the HPLC purity line standard on the product page.

Dubai/UAE Product Documentation

The live product page is the source of truth for price and stock. The table below mirrors the stable catalog facts — always check the current listing before ordering or a restock check.

Field Current Remy Peptides listing
Product pageTB-500 10mg Vial
Format10mg · Lyophilized research vial
Stock statusIn stock
AED price tierAED 290-350
COA routeCheck the product page and COA library; TB-500 is supplied to a >99% HPLC line standard for in-vitro research, with published Janoshik batch reports across the Retatrutide range in the library.
Use restrictionFor in-vitro laboratory research only. Not for human or veterinary use.

Supplier Checks for Research-Use Buyers

For Dubai and UAE research-supply searches, the cleanest buying checklist is evidence-light and verification-heavy. Before comparing any TB-500 10mg source, confirm:

Remy Peptides centralizes that workflow through the product page, the COA library, and contact verification. The same standard extends to the complete Dubai research-vial catalogue.

What This Page Does Not Claim

The research record helps define the compound, but it does not turn an RUO vial into a clinical product. Keep these boundaries in view:

Our Research Standards

This guide draws on the Remy TB-500 thymosin beta-4 research profile, live product-catalog data, and peer-reviewed and official sources. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Peptides

The Remy Peptides Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

TB-500 10mg Research FAQ

Can Dubai researchers buy TB-500 10mg from Remy Peptides?

Yes. Remy Peptides lists TB-500 10mg Vial as in stock for research-use-only orders in Dubai and the UAE. The live product page is the source of truth for current stock, AED pricing, and COA request details.

What format and price does Remy list for TB-500 10mg?

Remy Peptides lists TB-500 10mg as 10mg · Lyophilized research vial, with current AED tiers shown as AED 290-350. Prices, pack tiers, and orderability can change, so the product page should be checked before any research order.

What evidence does this TB-500 10mg guide cover?

This article summarizes compound identity, the strongest peer-reviewed evidence anchors, and the limits of translating regulated or preclinical findings to a research-use catalog vial. It is an evidence map, not a clinical-use guide.

Is TB-500 10mg sold for human or veterinary use?

No. Remy Peptides products are supplied strictly for in-vitro laboratory research. They are not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols.

Which page should researchers use next?

Use /product/tb-500-10mg for the live product facts, price tier, stock status, image, and COA route. Use the linked Remy Peptides profile or comparison article for deeper mechanism and evidence context.

Sources

  1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PMID: 16099219
  2. U.S. National Library of Medicine. ClinicalTrials.gov search results for RGN-259 / thymosin beta-4 ophthalmic studies. clinicaltrials.gov

For current stock, pricing, and COA route, use the live TB-500 10mg Vial page. For wider supplier verification, continue to the peptide COA guide and official contact verification.